The Pages section of GPnotebook comprises more than 30,000 concise, interlinked clinical reference articles, each focused on a specific primary care topic.
There are a number of new and updated GPnotebook resources well worth our attention this month. This newsletter is a taster, but hopefully as you ingest those I have selected here, you will be enticed to try others as well. On the theme of digestion, our entrée is an important public health discovery from China, which has international implications.
Entrée (read)
Gastric cancer is associated with multiple risk factors, including Helicobacter pylori. A vital question is this: would mass screening and eradication serve as an effective public health approach to reducing gastric cancer? (And if you are interested in an update on gastric cancer as a separate question, Dr Roger Henderson has recently released a helpful podcast addressing the full topic.)
To investigate this, a cluster-randomised, community-based trial was conducted in Linqu County, China. Individuals who tested positive for H. pylori via a 13C-urea breath test were randomly assigned to one of two intervention groups:
Those who tested negative for H. pylori received no treatment. The primary outcome measure was the incidence of gastric cancer. Over an 11.8-year follow-up period involving 180,284 eligible participants from 980 villages, 1035 cases of gastric cancer were recorded.
The data showed that individuals receiving the anti-H. pylori therapy had a modest reduction in cancer incidence in the intention-to-treat analysis (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.74–0.99). A somewhat larger effect was noted in those who achieved successful eradication (HR, 0.81; 95% CI, 0.69–0.96) compared with those whose treatment failed. The study authors concluded that these findings highlight the potential of mass screening and eradication as a public health policy for preventing gastric cancer.
For an Australian healthcare provider, this research is significant because it shifts the clinical conversation from simply managing H. pylori symptoms, to active cancer prevention. While Australia has a relatively low overall incidence of gastric cancer, I see some implications for daily practice:
Mains (watch)
For our main course, we tackle a meatier clinical dilemma: the direct head-to-head comparison of two heavyweight incretin therapies in the quest for cardiovascular and metabolic control.
Dr Lisa Devine has prepared a helpful video summary of the SURPASS-CVOT study, recently published in the New England Journal of Medicine. Of note, the trial was led by Professor Stephen Nicholls from Monash University, with 30 different countries involved. This study provides a robust, head-to-head comparison of two potent incretin therapies – tirzepatide and dulaglutide – in over 13,000 patients with type 2 diabetes and established cardiovascular disease.
The question being asked was whether tirzepatide was at least as effective as dulaglutide in reducing the time to the first occurrence of a major adverse cardiovascular event – a composite endpoint consisting of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. The primary finding was one of clinical reassurance: tirzepatide proved non-inferior to dulaglutide in preventing major adverse cardiovascular events, with an HR of 0.92. This suggests that, while it did not reach a definitive statistical threshold for superiority in heart protection, tirzepatide is at least as cardioprotective as one of our most trusted and established GLP-1 receptor agonists.
While the safety profiles were broadly similar, we must remain mindful of the higher frequency of gastrointestinal side effects associated with tirzepatide’s dual GIP/GLP-1 mechanism, particularly during dose titration. For the Australian GP, these results shift the clinical question away from whether we are protecting the heart and towards how much metabolic bonus we can achieve for our patients, allowing us to tailor therapy based on individual weight-loss goals and glycaemic targets without compromising on cardiovascular security.
While these metabolic gains are substantial enough to satisfy any clinical appetite, we must save room for a look at a malignancy that is often treated as a mere side dish despite its significant local impact.
Dessert (listen)
We conclude our clinical feast with a “dessert” that is anything but sweet: a discussion about the most common cancer in our sun-drenched country.
While we often dismiss basal cell carcinoma (BCC) as the “friendly” skin cancer, owing to its low mortality rate, Dr Roger Henderson reminds us that seriousness is a measure of morbidity and resource consumption, as much as mortality. As the most common cancer globally, its capacity for local destruction is significant, particularly as we see it appearing increasingly in younger cohorts.
It is a mistake to think of it as low concern just because it rarely metastasises; for example, a BCC on the medial canthus or alar rim is a high-stakes clinical challenge. When assessing for risk, we must look beyond cumulative UV exposure and consider the disproportionate impact of intense, intermittent sun exposure during teenage years, as well as the roles of chronic immunosuppression and arsenic exposure.
On examination, the classic “pearly papule with telangiectasia” is only one of many chameleons; BCCs often present with varied morphology and persist for years, frequently being mistaken for benign lesions. When managing these, we need to distinguish between the predictable, contained nodular subtype and the more ambitious infiltrative types that can track along nerves. While low-risk lesions are bread-and-butter for management in general practice (through surgery, cryotherapy or topicals like imiquimod), high-risk or recurrent cases require thoughtful referral – potentially for Mohs surgery or multidisciplinary team-led care involving emerging hedgehog inhibitors or immune checkpoint inhibitors.
Ultimately, a single BCC is a clear “canary in the coal mine” for future malignancies, necessitating a heightened surveillance schedule to mitigate a growing economic and patient-centred burden.
To receive monthly highlights by email, check your email newsletter preference settings.